Matching articles for "Infed"
Triferic for Iron Replacement
The Medical Letter on Drugs and Therapeutics • March 27, 2017; (Issue 1517)
The FDA has approved ferric pyrophosphate
citrate solution (Triferic – Rockwell Medical) to
maintain hemoglobin concentrations in adults with
hemodialysis-dependent chronic kidney disease.
Triferic is the...
The FDA has approved ferric pyrophosphate
citrate solution (Triferic – Rockwell Medical) to
maintain hemoglobin concentrations in adults with
hemodialysis-dependent chronic kidney disease.
Triferic is the first iron replacement product that is
added into the hemodialysis solution at each dialysis
procedure.
Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia
The Medical Letter on Drugs and Therapeutics • December 9, 2013; (Issue 1431)
The FDA has approved ferric carboxymaltose
(Injectafer – American Regent), a 2-dose intravenous
iron replacement product, for treatment of iron deficiency
anemia (IDA) in adults who cannot tolerate...
The FDA has approved ferric carboxymaltose
(Injectafer – American Regent), a 2-dose intravenous
iron replacement product, for treatment of iron deficiency
anemia (IDA) in adults who cannot tolerate or
have had an unsatisfactory response to oral iron and
in those who have non-dialysis-dependent chronic
kidney disease (CKD). It is the sixth IV iron product
approved in the US.
Correction: Ferumoxytol (Feraheme)
The Medical Letter on Drugs and Therapeutics • April 19, 2010; (Issue 1336)
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation
The Medical Letter on Drugs and Therapeutics • March 22, 2010; (Issue 1334)
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease....
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in chronic kidney disease and may be associated with decreased absorption from the gastrointestinal tract, limiting the usefulness of oral iron replacement. IV iron replacement can lower the dose requirement for erythropoiesis-stimulating drugs, particularly in patients on dialysis